---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-003344"
form_type: "8-K/A"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2024-01-05T23:59:59+00:00"
generated_at: "2026-06-07T03:09:16.238601+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Quince provides EryDel historical financials; FY2022 loss of €12.5M

## Summary
- EryDel net loss of €12.5M in 2022 vs. €17.3M in 2021; accumulated deficit €76.5M.
- As of Dec 2022, EryDel cash €1.3M, negative equity €16.5M; operating cash flow used €11.3M.
- Quince had $83.2M cash at Sep 30, 2023, expected to fund EryDex Phase 3 trial into at least 2026.
- Acquisition adds EryDel's Red Cell Loader platform and Phase 3 therapy for Ataxia-Telangiectasia.

## SEC filing metadata
- accession: 0001193125-24-003344
- form_type: 8-K/A
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2024-01-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312524003344/0001193125-24-003344-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312524003344/d109820d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-003344
- JSON: https://secwatch.observer/filing/0001193125-24-003344.json
- Plain text: https://secwatch.observer/filing/0001193125-24-003344.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.